These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 36282460)

  • 1. Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation/atrial flutter in heart failure patients with reduced ejection fraction: a meta-analysis of randomized controlled trials.
    Sfairopoulos D; Liu T; Zhang N; Tse G; Bazoukis G; Letsas K; Goudis C; Milionis H; Vrettos A; Korantzopoulos P
    Heart Fail Rev; 2023 Jul; 28(4):925-936. PubMed ID: 36282460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective Effects of Sodium-Glucose Transporter 2 Inhibitors on Atrial Fibrillation and Atrial Flutter: A Systematic Review and Meta- Analysis of Randomized Placebo-Controlled Trials.
    Li D; Liu Y; Hidru TH; Yang X; Wang Y; Chen C; Li KHC; Tang Y; Wei Y; Tse G; Xia Y
    Front Endocrinol (Lausanne); 2021; 12():619586. PubMed ID: 33815278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials.
    Li WJ; Chen XQ; Xu LL; Li YQ; Luo BH
    Cardiovasc Diabetol; 2020 Aug; 19(1):130. PubMed ID: 32847602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide Receptor Agonists for Atrial Fibrillation in Type 2 Diabetes Mellitus: Systematic Review With Network Meta-analysis of Randomized Controlled Trials.
    Li W; Chen X; Xie X; Xu M; Xu L; Liu P; Luo B
    J Cardiovasc Pharmacol; 2022 Mar; 79(3):281-288. PubMed ID: 34935705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effectiveness of SGLT2 inhibitor in the incidence of atrial fibrillation/atrial flutter in patients with type 2 diabetes mellitus/heart failure: a systematic review and meta-analysis.
    Wang M; Zhang Y; Wang Z; Liu D; Mao S; Liang B
    J Thorac Dis; 2022 May; 14(5):1620-1637. PubMed ID: 35693625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of SGLT-2 inhibitors on arrhythmia events: insight from an updated secondary analysis of > 80,000 patients (the SGLT2i-Arrhythmias and Sudden Cardiac Death).
    Liao J; Ebrahimi R; Ling Z; Meyer C; Martinek M; Sommer P; Futyma P; Di Vece D; Schratter A; Acou WJ; Zhu L; Kiuchi MG; Liu S; Yin Y; Pürerfellner H; Templin C; Chen S
    Cardiovasc Diabetol; 2024 Feb; 23(1):78. PubMed ID: 38402177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
    Li HL; Lip GYH; Feng Q; Fei Y; Tse YK; Wu MZ; Ren QW; Tse HF; Cheung BY; Yiu KH
    Cardiovasc Diabetol; 2021 May; 20(1):100. PubMed ID: 33962654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of SGLT2 inhibitors on cardiovascular events in patients with atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials.
    Zheng S; Lai Y; Jiang C; He L; Zhao Z; Li W; Tang R; Sang C; Long D; Du X; Ma C; Dong J
    Pacing Clin Electrophysiol; 2024 Jan; 47(1):58-65. PubMed ID: 38010824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis.
    Li C; Yu J; Hockham C; Perkovic V; Neuen BL; Badve SV; Houston L; Lee VYJ; Barraclough JY; Fletcher RA; Mahaffey KW; Heerspink HJL; Cannon CP; Neal B; Arnott C
    Diabetes Obes Metab; 2022 Oct; 24(10):1927-1938. PubMed ID: 35589614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial.
    Zelniker TA; Bonaca MP; Furtado RHM; Mosenzon O; Kuder JF; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Budaj A; Kiss RG; Padilla F; Gause-Nilsson I; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
    Circulation; 2020 Apr; 141(15):1227-1234. PubMed ID: 31983236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists.
    Scheen AJ
    Diabetes Metab; 2022 Nov; 48(6):101390. PubMed ID: 36170946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a post-hoc analysis of the ATHENA trial.
    Vaduganathan M; Piccini JP; Camm AJ; Crijns HJGM; Anker SD; Butler J; Stewart J; Braceras R; Albuquerque APA; Wieloch M; Hohnloser SH
    Eur J Heart Fail; 2022 Jun; 24(6):1094-1101. PubMed ID: 35293087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-glucose cotransporter 2 inhibitor may not prevent atrial fibrillation in patients with heart failure: a systematic review.
    Ouyang X; Wang J; Chen Q; Peng L; Li S; Tang X
    Cardiovasc Diabetol; 2023 May; 22(1):124. PubMed ID: 37226247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) with Cardiac Arrhythmias: A Systematic Review and Meta-Analysis of Cardiovascular Outcome Trials.
    Wang X; Zhang X; Zhang W; Li J; Weng W; Li Q
    Rev Cardiovasc Med; 2023 Sep; 24(9):258. PubMed ID: 39076384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure.
    Patel RB; Vaduganathan M; Rikhi A; Chakraborty H; Greene SJ; Hernandez AF; Felker GM; Redfield MM; Butler J; Shah SJ
    JACC Heart Fail; 2019 Jan; 7(1):47-55. PubMed ID: 30409707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of different hypoglycemic drugs and insulin on the risk of new-onset atrial fibrillation in people with diabetes: a network meta-analysis.
    Lv Q; Yang Y; Lv Y; Wu Q; Hou X; Li L; Ye X; Yang C; Wang S
    Eur J Med Res; 2024 Jul; 29(1):399. PubMed ID: 39085898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence, pathophysiology, and clinical significance of post-heart transplant atrial fibrillation and atrial flutter.
    Ahmari SA; Bunch TJ; Chandra A; Chandra V; Ujino K; Daly RC; Kushwaha SS; Edwards BS; Maalouf YF; Seward JB; McGregor CG; Chandrasekaran K
    J Heart Lung Transplant; 2006 Jan; 25(1):53-60. PubMed ID: 16399531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of cardiac resynchronization therapy in patients with intermittent atrial fibrillation or atrial flutter in the COMPANION trial.
    Kalscheur MM; Saxon LA; Lee BK; Steinberg JS; Mei C; Buhr KA; DeMets DL; Bristow MR; Singh SN
    Heart Rhythm; 2017 Jun; 14(6):858-865. PubMed ID: 28323173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis.
    Zhou Z; Jardine MJ; Li Q; Neuen BL; Cannon CP; de Zeeuw D; Edwards R; Levin A; Mahaffey KW; Perkovic V; Neal B; Lindley RI;
    Stroke; 2021 May; 52(5):1545-1556. PubMed ID: 33874750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Sodium-Glucose Co-transporter Protein 2 Inhibitors on Arrhythmia in Heart Failure Patients With or Without Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.
    Yin Z; Zheng H; Guo Z
    Front Cardiovasc Med; 2022; 9():902923. PubMed ID: 35665272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.